Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
endoscopic remission rate at 12 months
Timeframe: 12 months after first intervention administration
normalization rate of serum biomarker at 12 months
Timeframe: 12 months after first intervention administration
clinical remission rate at 12 months
Timeframe: 12 months after first intervention administration
clinical response rate at 12 months
Timeframe: 12 months after first intervention administration
endoscopic response rate at 12 months
Timeframe: 12 months after first intervention administration
life quality changes at 12 months
Timeframe: 12 months after first intervention administration
endoscopic remission rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
normalization rate of serum biomarker after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
clinical remission rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
clinical response rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
endoscopic response rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
life quality changes after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration